A $4.7 million collaboration led by the National Cancer Centre Singapore will develop a clinical-grade test using AI and ...
The key for optimizing cell-line development for antibody derivatives might just be to prioritize early assessment of product ...
Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode (TM) Whole ...
BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study ...
Rare cancers encompass a heterogeneous group of malignancies characterized by low incidence and prevalence but, often, disproportionately high mortality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results